O74036 (RADA_PYRFU) Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1)

DNA repair and recombination protein RadA UniProtKBInterProSTRINGInteractive Modelling

349 aa; Sequence (Fasta) ; 3 identical sequences: Pyrococcus woesei: A0A0D3MA54; Pyrococcus furiosus: A0A5C0XRY0; Pyrococcus furiosus COM1: I6V3I0

Available Structures

65 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Rad51 (RadA) Heteromer
35-349
14×SO4; 18×IMD; 18×GOL;MPD;
Assess
HUMANISED MONOMERIC RADA IN COMPLEX WITH OLIGOMERISATION PEPTIDE Heteromer
94-349
PO4;GOL;
Assess
Stapled peptide SP24 in complex with humanised RadA mutant HumRadA22 Heteromer
P51587;
110-349
ADP;RF6;
Assess
Stapled peptide SP30 in complex with humanised RadA mutant HumRadA22 Heteromer
P51587;
111-349
ADP;MG;RF6;
Assess
Stapled peptide SP2 in complex with humanised RadA mutant HumRadA22 Heteromer
P51587; Q06609;
111-349
TKI;
Assess
Apo-structure of humanised RadA-mutant humRadA22Fmonomer108-349
CL;
Assess
Structure of unliganded HumRadA1.2monomer108-349
PO4;
Assess
HUMANISED MONOMERIC RADA IN COMPLEX WITH FHTU TETRAPEPTIDEmonomer108-349
PO4;
Assess
Humanised monomeric RadA in complex with FHTA tetrapeptidemonomer108-349
PO4;
Assess
Structure of unliganded HumRadA1.6monomer108-349
PO4;
Assess
HumRadA1 in complex with 5-Ethyl-N-(1H-indol-5-ylmethyl)-1,3,4-thiadiazol-2-amine in P21monomer108-349
PO4;O1E;
Assess
HumRadA1 soaked with 5 mM indazole in 10% DMSOmonomer108-349
LZ1;DMS;PO4;
Assess
HumRadA1 soaked with 2 mM indazole in 10% DMSOmonomer108-349
LZ1;PO4;
Assess
HumRadA1 as soaking control with 10% DMSOmonomer108-349
PO4;DMS;
Assess
HumRadA1 soaked with 10 mM indazole in 10% DMSOmonomer108-349
LZ1;PO4;
Assess
HumRadA1 soaked with 1 mM indazole in 10% DMSOmonomer108-349
PO4;
Assess
HumRadA1 soaked with 0.5 mM indazole in 10% DMSOmonomer108-349
PO4;
Assess
Structure of unliganded HumRadA1.3monomer108-349
PO4;
Assess
HumRadA1.2 soaked with napht-2,3-diol for 5 minutes at 20 mMmonomer108-349
D48;PO4;
Assess
HumRadA1.2 soaked with napht-2,3-diol for 10 minutes at 20 mMmonomer108-349
D48;PO4;
Assess
HUMANISED MONOMERIC RADA IN COMPLEX WITH FHAA TETRAPEPTIDEmonomer108-349
PO4;GOL;
Assess
Humanised monomeric RadA in complex with indazolemonomer108-349
PO4;LZ1;
Assess
Apo-structure of humanised RadA-mutant humRadA28monomer108-349
SO4;MPD;MRD;CL;
Assess
HumRadA1 soaked with 0.2 mM indazole in 10% DMSOmonomer108-349
PO4;
Assess
MONOMERIC RADA IN COMPLEX WITH FATA TETRAPEPTIDEmonomer108-349
PO4;
Assess
Structure of humanised RadA-mutant humRadA22F in complex with 1-Indane-6-carboxylic acidmonomer108-349
NA;CA;6FZ;GOL;
Assess
HumRadA1.2 soaked with napht-2,3-diol for 30 seconds at 20 mMmonomer108-349
D48;PO4;
Assess
HumRadA1.2 soaked with napht-2,3-diol overnight at 20 mMmonomer108-349
D48;PO4;
Assess
HumRadA2 in complex with Naphthyl-HPA fragment-peptide chimeramonomer108-349
PO4;O0E;
Assess
Structure of humanised RadA-mutant humRadA22F in complex with indole-6-carboxylic acidmonomer108-349
1F1;NA;CA;DMS;
Assess
HumRadA1.2 soaked with napht-2,3-diol overnight at 2 mMmonomer108-349
D48;PO4;
Assess
Humanised monomeric RadA in complex with 4-methylester indolemonomer108-349
PO4;4ME;
Assess
HumRadA1.2 soaked with napht-2,3-diol overnight at 5 mMmonomer108-349
D48;PO4;
Assess
HumRadA1.2 soaked with napht-2,3-diol overnight 10 mMmonomer108-349
D48;PO4;
Assess
Apo-structure of humanised RadA-mutant humRadA3monomer108-349
CA;
Assess
HumRadA1.2 soaked with napht-2,3-diol for 60 seconds at 20 mMmonomer108-349
D48;PO4;
Assess
HumRadA1.2 soaked with napht-2,3-diol overnight at 1 mMmonomer108-349
D48;PO4;
Assess
RADA C-TERMINAL ATPASE DOMAIN FROM PYROCOCCUS FURIOSUS BOUND TO AMPPNPmonomer108-349
ANP;GOL;MG;
Assess
RadA C-terminal ATPase domain from Pyrococcus furiosusmonomer108-349
PO4;
Assess
Humanised monomeric RadA in complex with napht-2-olmonomer108-349
PO4;1NP;
Assess
HUMANISED MONOMERIC RADA IN COMPLEX WITH FHPA TETRAPEPTIDEmonomer108-349
PO4;
Assess
HumRadA1 in complex with 3-amino-2-naphthoic acidmonomer108-349
NYE;PO4;GOL;
Assess
Humanised monomeric RadA in complex with napht-1-olmonomer108-349
PO4;03V;
Assess
Apo-structure of humanised RadA-mutant humRadA4monomer108-349
PO4;
Assess
Humanised monomeric RadA in complex with L-methylester tryptophanmonomer108-349
PO4;TR7;
Assess
HumRadA22F in complex with CAM833monomer108-349
O08;CA;GOL;
Assess
HumRadA1 in complex with 5-Ethyl-N-(1H-indol-5-ylmethyl)-1,3,4-thiadiazol-2-amine in P21212monomer108-349
PO4;O1E;
Assess
RadA C-terminal ATPase domain from Pyrococcus furiosus bound to ATPmonomer108-349
MG;ATP;
Assess
Humanised monomeric RadA in complex with 2-amino benzothiazolemonomer108-349
PO4;ABV;
Assess
Humanised monomeric RadA in complex with 5-methyl indolemonomer108-349
PO4;5MI;
Assess
HumRadA22F in complex with compound 6monomer108-349
NZW;CA;
Assess
HUMANISED MONOMERIC RADA IN COMPLEX WITH FHTG TETRAPEPTIDEmonomer108-349
PO4;
Assess
Leishmania infantum Rad51 surrogate LiRadA10 in complex with 5,6,7,8-tetrahydro-2-naphthoic acidmonomer108-349
PO4;NY5;
Assess
Structure of humanised RadA-mutant humRadA22F in complex with peptide FHTAmonomer108-349
DMS;CA;
Assess
HUMANISED MONOMERIC RADA IN COMPLEX WITH WHTA TETRAPEPTIDEmonomer108-349
PO4;
Assess
RADA C-TERMINAL ATPASE DOMAIN FROM PYROCOCCUS FURIOSUS BOUND TO ADPmonomer108-349
ADP;MG;NA;
Assess
Humanised monomeric RadA in complex with 5-hydroxy indolemonomer108-349
PO4;5H1;
Assess
Structure of unliganded HumRadA1.4monomer108-349
Assess
Apo-structure of humanised RadA-mutant humRadA22monomer108-349
SO4;
Assess
Apo-structure of humanised RadA-mutant humRadA2monomer108-349
Assess
Apo-structure of humanised RadA-mutant humRadA26Fmonomer109-349
CA;
Assess
RadA C-terminal ATPase domain from Pyrococcus furiosus bound to GTPmonomer109-349
GTP;MG;GOL;
Assess
Apo-structure of humanised RadA-mutant humRadA14monomer109-349
Assess
Apo-structure of humanised RadA-mutant humRadA33Fmonomer110-349
CL;SO4;
Assess
HumRadA33F in complex with peptidic inhibitor 6monomer111-349
NZW;SO4;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
1pzn.1.Hhomo-14-mer0.8135-349
16×IMD;100.00
Assess